Target Validation Information
TTD ID	T99954
Target Name	Prostacyclin receptor (PTGIR)
Type of Target	Successful
Drug Potency against Target	Epoprostenol	Drug Info	Kd = 16 nM	[6]
	Misoprostol	Drug Info	IC50 = 6.17 nM	[4]
	Treprostinil	Drug Info	EC50 = 8.2 nM	[5]
	AP-227	Drug Info	IC50 = 150 nM
	FR-181157	Drug Info	IC50 = 1200 nM	[2]
	FR-193262	Drug Info	Ki = 12 nM	[1]
	LAROPIPRANT	Drug Info	Ki = 6628 nM	[3]
References
REF 1	Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3279-83.
REF 2	Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4861-4.
REF 3	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
REF 4	Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Br J Pharmacol. 1992 Apr;105(4):817-24.
REF 5	A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010 Jan;104(1):9-21.
REF 6	Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br J Clin Pharmacol. 1983 Jan;15(1):77-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.